Last reviewed · How we verify
Hyperbaric prilocaine
At a glance
| Generic name | Hyperbaric prilocaine |
|---|---|
| Also known as | Tachipri |
| Sponsor | Centre Hospitalier Universitaire Saint Pierre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Using Three Different Doses of Hyperbaric Prilocaine 2% Local Anaesthetic ( 40,50 and 60mg ),Through Spinal Anaesthesia in Knee Arthroscopy Patients to Compare Time to Void (PHASE3)
- Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine in Spinal Anaesthesia (PHASE4)
- Spinal Anesthesia by Hyperbaric Prilocaine in Day-Case Perianal Surgery (NA)
- Low Dose Bupivacaine Versus Prilocaine Regarding Hemodynamic Stability and Safety in Geriatrics (PHASE1, PHASE2)
- Intrathecal Prilocaine and Adductor Canal Block vs Intrathecal Bupivacaine Alone for Ambulatory Knee Arthroscopy (PHASE4)
- Effect of Subarachnoid Block and Femoropopliteal Block to Limb Perfusion in PAD Patients (NA)
- Hyperbaric Prilocaine 2% vs Hyperbaric Bupivacaine 0.5% in Caesarean Section (EARLY_PHASE1)
- A Comparative Study on Three Different Doses of Intrathecal Hyperbaric Prilocaine With Fentanyl for Optimal Dose to be Used in Elderly Patients Undergoing Day Case Lower Abdominal and Urologic Surgeries. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperbaric prilocaine CI brief — competitive landscape report
- Hyperbaric prilocaine updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Saint Pierre portfolio CI